Trastuzumab (Herclon?, Herceptin?) is a recombinant DNA-derived humanized monoclonal antibody that selectively targets the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2). Trastuzumab has antitumor activity against HER2-positive human breast tumor cells in laboratory models and is active for the treatment of women with HER2-overexpressing breast cancers. In HER2 overexpressing cells, trastuzumab markedly down-regulates HER2 expression by accelerating receptor endocytosis and degradation and inhibits cell cycle progression by inducing the formation of p27Kip1/Cdk2 complexes. However, some patients develop unwanted immunogenicity, which leads to production of anti-drug-antibodies (ADAs) inactivating the therapeutic effects of the treatment and, in rare cases, inducing adverse effects. BioVision’s BioSimTM anti-Trastuzumab ELISA kit is designed to quantify/measure the antibody against Trastuzumab with high specificity and sensitivity in biological matrices.
產品特點
. It is convenient to obtain blood sample just before the infusion of Trastuzumab or at least 2 weeks after the infusion of Trastuzumab
Recovery rate: 85 – 115% with normal human serum samples with known concentrations
